Sionna Therapeutics (SION) Operating Expenses (2024 - 2026)

Sionna Therapeutics has disclosed Operating Expenses across 3 years of filings, most recently posting $29.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $29.6 million, up 50.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.9 million (up 28.36% YoY), and the FY2025 annual result was $89.0 million, up 26.12% from the prior year.
• Operating Expenses came in at $29.6 million for Q1 2026 at Sionna Therapeutics, up from $23.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $29.6 million in Q1 2026 to a low of $11.3 million in Q2 2024.
• The 3-year median for Operating Expenses is $21.9 million (2025), against an average of $21.0 million.
• Peak annual rise in Operating Expenses reached 94.0% in 2025, while the deepest fall reached 14.93% in 2025.
• Sionna Therapeutics' Operating Expenses stood at $18.1 million in 2024, then surged by 30.22% to $23.6 million in 2025, then grew by 25.36% to $29.6 million in 2026.
• The last three Operating Expenses figures came in at $29.6 million (Q1 2026), $23.6 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.